key: cord-0886621-4trkb2bn
authors: Laurini, Erik; Marson, Domenico; Aulic, Suzana; Fermeglia, Alice; Pricl, Sabrina
title: In Silico Molecular-Based Rationale for SARS-CoV-2 Spike Circulating Mutations Able to Escape Bamlanivimab and Etesevimab Monoclonal Antibodies
date: 2021-05-18
journal: bioRxiv
DOI: 10.1101/2021.05.18.444605
sha: baf609e85d8b510147d378e950bfc6a0432d5ac1
doc_id: 886621
cord_uid: 4trkb2bn

The purpose of this work was to provide an in silico molecular rationale of the role eventually played by currently circulating S-RBDCoV-2 mutations in evading the immune surveillance effects elicited by the two Eli Lilly LY-CoV555/bamlanivimab and LY-CoV016/etesevimab monoclonal antibodies. The main findings from this study and shows that, compared to the wild-type SARS-CoV-2 spike protein, mutations E484A/G/K/Q/R/V, Q493K/L/R, S494A/P/R, L452R and F490S are predicted to be markedly resistant to neutralization by LY-CoV555, while mutations K417E/N/T, D420A/G/N, N460I/K/S/T, T415P, and Y489C/S are predicted to confer LY-CoV016 escaping advantage to the viral protein. A challenge of our global in silico results against the relevant experimental data resulted in an overall 90% agreement. This achievement not only constitutes a further, robust validation of our computer-based approach but also yields a molecular-based rationale for all relative experimental findings, and leads us to conclude that the current circulating SARS-CoV-2 and all possible emergent variants carrying these mutations in the spike protein can present new challenges for mAb-based therapies and ultimately threaten the fully-protective efficacy of currently available vaccines.

their clinical benefit is still a matter of debate. 7 Meanwhile, different mRNA-or virus-based vaccines have received approval (and more are under clinical trial) and have so far provided effective and efficient protection against the disease, 8, 9 making vaccination the key weapon in fighting the COVID-19 pandemic. Another promising approach is the isolation of SARS-CoV-2 neutralizing monoclonal antibodies (mAbs). 10, 11 mAbs are immuno-therapeutics, which could i) potentially deliver immediate benefit in COVID-19 treatment, ii) act as passive prophylaxis until vaccines become globally available, and iii) serve as alternative therapeutic strategies in those populations where vaccines have been found to be less protective. 11, 12 The recent findings that ansuvimab (mAb114) is a safe and effective treatment for symptomatic infection with Ebola virus is a notable example of the successful use of mAb therapy during an outbreak of infectious disease. 13 Ab-based therapeutics directed against SARS-CoV-2 still present lights and shadows. 14 Preclinical data and phase-III clinical studies indicate that mAbs could be effectively deployed for prevention or treatment during the viral symptoms phase of the disease. 15 Cocktail formulations of two or more mAbs are preferred over single Ab preparations because these combinations may result in increased antiviral efficacy and viral escape prevention. [16] [17] [18] However, Ab cocktails are complicate formulations, 19, 20 and such approach likely involves increased production costs and quantities at a time when the supply chain is being pressured into meeting the high demand for COVID-19 therapeutics, vaccines, and therapeutic agents in general.

The multi-domain SARS-CoV-2 surface spike (S) protein 21-23 -a trimeric class I fusion protein that mediates viral entry -is the focus of the current Ab discovery efforts. The S protein is composed of two subunits: S1, containing a receptor-binding domain (S-RBD CoV-2 ) that recognizes and binds the human receptor, the angiotensin-converting enzyme 2 (ACE2), [24] [25] [26] [27] and S2, which mediates viral cell membrane fusion by forming a six-helical bundle via the two-4 heptad repeat domain. Viral entry is initiated by the upward shift of the spike RBD at the protein's apex which, in turn, promotes ACE2 binding (Figure 1 , top panels). In addition, viral cell entry involves the S-protein priming operated by the cellular transmembrane serine protease 2 (TMPRSS2), 28 along with other proteases, 29 the removal of subunit S1, and the conformational reorganization of subunit S2; all these processes contribute to viral fusion with the cell and transfers of genetic material following receptor involvement. Due to the critical nature of the viral S-RBD CoV-2 interaction with ACE2, Abs that bind this domain and interfere with ACE2 attachment can have potent neutralizing activity. [30] [31] [32] [33] [34] [35] [36] [37] An S-RBD CoV-2 specific mAb (LY-CoV555 or bamlanivimab) was discovered that can bind the RBD in both (up/active) (bottom panel in Figure 1 ) and (down/resting) conformations, and was reported to display high in vitro and in vivo protection potency, thereby supporting its development as a therapeutic for the treatment and prevention of COVID-19. 38 In the same context, another mAb isolated from a COVID-19 convalescent patient -LY-CoV016 or etesevimab -was soon after reported. 39 This mAb also showed specific SARS-CoV-2 neutralization activity by recognizing another epitope on the S-RBD CoV-2 , and was found effective in vivo in both prophylactic and therapeutic settings. 39 These two mAbs from Eli Lilly presently under clinical evaluation for the treatment and prevention of COVID-19, both alone and in cocktail formulations. [40] [41] [42] Contextually, in the United States the Food and Drug Administration (FDA) has already granted Emergency Use Authorization (EUA) of the combined bamlanivimab/etesevimab cocktail as anti-SARS-CoV-2 monoclonal antibody therapeutic for the treatment of COVID-19, while the European Medicine Agency (EMA) also recently concluded that these two mAbs can be used together to treat confirmed COVID-19 in patients who do not require supplemental oxygen and who are at high risk of their COVID-19 disease becoming severe. EMA also analyzed the use of LY-CoV555 alone and concluded that, despite uncertainties around the benefits of monotherapy, it could be considered a treatment option.

However, viruses that encode their genome in RNA (e.g., SARS-CoV-2, the Human Immunodeficiency Virus (HIV) and the Influenza A Virus (IAV)), are prone to acquire 6 mutations in time, mainly because of three factors. The first, and likely the most probable source of mutations consists in copying errors as viruses replicate inside host cells. 43 Interestingly, however, this mechanism may be less relevant for SARS-CoV-2 with respect to other RNA viruses, since coronavirus polymerasesi.e., those enzymes the play vital role in viral genome replication and transcription -are endowed with a proofreading mechanism that corrects potentially fatal mistakes. 44 Viral genomic variability may also originate from the recombination of two viral lineages coinfecting the same host. 45 As a third factor, mutations can be induced by the host cell RNA-editing systems, which form part of host natural immunity. 46, 47 A further element of complexity is reported in the recent work by Di Giorgio et al., 47 according to which both the adenosine deaminases acting on RNA (ADAR) and the apolipoprotein B mRNA editing catalytic polypeptide-like (APOBEC) families of proteins are involved in coronavirus genome editing -a process that may change the fate of both virus and patient.

Whatever the case, the lesson learned from RNA virus genetics and epidemiology is that mutations are an inevitable consequence of being a virus. 48 Yet, we also know that those mutations that adversely impact any of the vital steps of virus function are swiftly eliminated by natural selection. On the contrary, neutral variations and especially those mutations that endow the virus with a competitive advantage can reach high frequencies.

Thus far, a steadily increasing number of SARS-CoV-2 genetic variants have been emerging and circulating all over the world since the beginning of the COVID-19 pandemic. Although all proteins encoded in the SARS-CoV-2 RNA are continuously reported and catalogued in the plethora of databased and networks dedicated to COVID-19 genomic surveillance, 49 the spike protein is the one more often and constantly reported mutated in the viral genomes sequenced worldwide. 50 In this respect, both the United States Center for Disease Control and Prevention (CDC) and the equivalent European agency (ECDC), in collaboration with the World Health Organization (WHO) and several governmental authorities and working groups have 7 developed a SARS-CoV-2 variant classification schema that groups all major viral variants into main groups: variants of high consequence (VOHC, CDC), variants of concern (VOC), variants of interest (VOI) and variants under monitoring (VUM, ECDC), depending on their associated degree of impact on transmissibility, severity and/or reduced neutralization by antibody/efficacy of Ab treatments (of note, European and US classification may not fully coincide since the importance of variants may differ by location). At present no SARS-CoV-2 circulating variants have been classified as VOHC, while a substantial number them have been marked as VOC and VOI/VUM by CDC 51 and ECDC, 52 and all of them are characterized by the presence of at least one spike mutation of interest (MOI) 52 (see the Conclusion section for a more detailed discussion on this subject). The ability of SARS-CoV-2 mAbs to select any of these variants that is apparently fit and that naturally occurs even at low frequencies in circulating viral populations suggests that the therapeutic use of single mAb might select for escape mutants, although the extent to which resistance will impact the effectiveness of Abs in SARS-CoV-2 therapeutic and vaccine settings is still a matter of intense investigation. 10, [53] [54] [55] In this arena, the purpose of this work is to provide an atomistic-based, in silico perspective of the role eventually played by currently circulating S-RBD CoV-2 mutations in escaping binding of the two mAbs bamlanivimab and etesevimab as a proof of concept. A computational alanine scanning (CAS) mutagenesis 56 initially allowed us to identify the main molecular determinants of each Ab/S-RBD CoV-2 recognition; then, each spike residues that, according to the CAS results, contributes to the relevant viral protein/mAb binding interface was mutated into all currently reported circulating mutations at that position, 57 and the corresponding variation in affinity of all mutated spikes for each mAb with respect to the wild-type viral protein was estimated using a consolidate protocol. 58 To quickly and effectively ranking the different spike mutants with respect to their mAb escaping potential, a color-coded criterion based on the predicted free energy difference range of values was adopted, as shown in Table 1 . Of note, 8 this criterion is identical to the one we adopted and validated in our previous work for ranking the effect of both ACE2 and S-RBD CoV-2 mutations on their mutual binding. 58 of which locate on the heavy chain (HC) and 5 on the light chain (LC), respectively ( Figure   2A and Table S1 ). Tables S2-S3 .

The results from the CAS ( Figure 2B -C) identify both the S protein and the LY-CoV555 mAb residues that afford a significant contribution to the binding interface. Furthermore, CAS data clearly indicate residues E484, Q493 and S494 on the S-RBD CoV-2 and R H 50, R H 96, E H 102, and R H 104 on the mAb heavy chain as key positions contributing to shaping and determining the stability of the relevant protein−protein interface, as discussed in details below.

E484. The confirmation of the E484 as a crucial residue was an expected result as a glutamic acid (E) to lysine (K) substitution at this position (E484K) in the S-RBD CoV-2 is present in the rapidly spreading variants of concern belonging to the B. Figure 3A , Table S1 ).

When E484 is replaced with alanine in CAS, these interface-stabilizing interactions -along with the slightly beneficial contribution from the intramolecular van der Waals contact with the two Ab HC tyrosines -are no longer made, reflecting a loss of the corresponding binding free energy of ΔΔG CoV-2 (E484A) = −5.92 ± 0.12 kcal/mol ( Figure 2B , Table S2 ).

Contextually, the corresponding values of ΔΔG LY-CoV555 (R H 50A) = −3.02 ± 0.19 kcal/mol and ΔΔG LY-CoV555 (R L 96A) = −2.59 ± 0.11 kcal/mol ( Figure 2C , Table S3 ) are in line with the important contribution these residues provide to the formation of the corresponding viral protein/antibody interface described above ( Figure 3A ). Hydrogen bonds (HBs) and salt bridges (SBs) are represented as dark green and dark red broken lines, respectively, and the relevant average distances are reported accordingly. Further important HBs and SBs detected in each complex are also indicated using light green/red broken lines and light gray labels (see Table S1 for details). Table S1 ). Thus, abrogation of these intermolecular contacts by replacing the wild-type glutamine with alanine is accompanied by a ~4.2 kcal/mol loss in binding free energy (ΔΔG CoV-2 (Q493A) = −4.18 ± 0.14 kcal/mol, Figure 2B , Table S2 ).

Similarly, when either of the two LY-CoV555 residues E H 102 or R H 104 are mutated into alanine, the related values of ΔΔG nicely reflect their importance in binding S-RBD CoV-2 , as Table S3 ). Of note, these two mAb amino acids are engaged in a fundamental internal SB (2.76 ± 0.11 Å, Figure 3B , Table S1 ) that appears to play a major structural role in properly orienting their side chains for binding both Q493 and another

spike key residue -S494 -as discussed below.

S494. Serine 494 is an interesting SARS-CoV-2 RBD residue that has been previously reported by us to form an internal HB with the side chain of the adjacent Q493, instrumental to direct the latter in H-bridging aspartic acid 35 (D35) on the human ACE2 across their binding interface. 56, 58 When in complex with LY-CoV555, S494 engages the side chains of the LY-CoV555 mAb residues E H 102 and R H 104 in two intermolecular HBs (2.86 ± 0.16 Å and 3.18 ± 0.19 Å, respectively), alongside a strong polar interaction with the viral N31 ( Figure 3B , Table S1 ). Thus, the S494A mutation actually shows a considerable variation in the corresponding ΔΔG value (ΔΔG CoV-2 (S494A) = −4.02 ± 0.12 kcal/mol, Figure 2B , Table S2) making S494 the spike third protein/protein key residue.

V483, F486, and Y489. Predictably, the SARS-CoV-2 RBD residues V483, F486, and Y489

afford only a network of stabilizing intermolecular CIs to the viral protein/antibody binding interface region centered around the nearby key residue E484 ( Figure 3A ). Specifically, the side chain of V483 interactsvia van der Waals/hydrophobic contacts -with the side chains of W H 47, R H 50 and N H 59 on the Ab HC, and the side chains of T L 94 and R L 96 on the Ab LC, 13 respectively ( Figure 3A , Table S1 ). Contextually, the phenyl ring of F486 engages two p/p stacking interactions involving the side chains of the Ab LC Y L 32 and Y L 92, while the aromatic moiety of Y489 establish dispersive/polar interactions with the LY-CoV555 residues Y H 110 and Y L 32 on the Ab HC and LC, respectively ( Figure 3A , Table S1 ). The absence of these CIs when each of these residues is mutated into alanine reflects the moderate variations of the corresponding free energy of binding ( Figure 2B , Table Figure 3B , Table S1 ). L452 contacts the side chains of I H 54 and L H 55 on the LY-Cov555

Ab HC, while the last two spike residues T470 and F490 exchange nonpolar interactions with the side chains of the Ab HC residues I H 52, I H 54, L H 55 and I H 57, in addition to the p/p stacking observed between F490 and the Ab HC Y H 101 ( Figure 3B , Table S1 ). This is supported by the calculated ΔΔG value obtained by changing these amino acids into alanine Figure 2B , Table S2 ). Table 1 .

E484. The CAS results discussed above clearly show that glutamic acid at the position 484 along the S protein wild-type sequence (E484) is a key player in the LY-CoV555/S-RBD CoV-2 interaction ( Figures 2B and 3A , Tables S1-S2). Interesting, replacing the viral spike E484 with each of the alternative residues considered (i.e., E484A/D/G/K/Q/R/V) reflects into a robust interface disrupting behavior, with the mild exception of the E484D substitution ( Figure 4A , Figure S1 , and Tables S4-S5). Figure 4B shows the results for the E484K as a representative example. As seen from this Figure and Y H 32 on the LY-CoV555 mAb remains almost unperturbed ( Figure 4B , Figure S1 , Table   S5 ). Table S4 , Figures S1, and Table S5 . In this and all other similar figures, the colored boxes below each bar in the graphs show the classification of the destabilizing effects of the corresponding mutation on the S-RBD CoV-2 /LY-CoV555 mAb complex. Color legend: gray, neutral mutations; light yellow, mildly destabilizing mutations; light red, destabilizing mutations; red, highly destabilizing mutations (see Table 1 ). (B) Main interactions involving the S-RBD CoV-2 E484K mutant at the interface with the LY-CoV555 (bamlanivimab) mAb as obtained from the relevant equilibrated MD simulation. Images for all other A/D/G/Q/R and V mutants are shown in Figure S1 (see also Table S5 for details). Colors and other explanations are the same as in Figure 3 .

An utterly similar situation is observed in the presence of the A, G, R, and V mutants (see Figure S1 and Table S5 for details). In line with this, the predicted changes in binding free energy for the replacement of the wild-type E484 with A/G/K/R/V in the S-RBD CoV-2 /LY-CoV555 relevant complexes (ΔΔG CoV-2 (E484A) = −6.18 ± 0.10 kcal/mol,

ΔΔG CoV-2 (E484G) = −7.58± 0.18 kcal/mol, ΔΔG CoV-2 (E484K) = −7.83 ± 0.11 kcal/mol, ΔΔG CoV-2 (E484R) = −7.99 ± 0.12 kcal/mol, ΔΔG CoV-2 (E484V) = −6.02 ± 0.14 kcal/mol, Figure 4A and Table S4 ) support the prominent contribution played by this residue in anchoring the viral protein/LY-CoV555 mAb binding interface and the LY-CoV555 escaping potential of the E484A, E484G, E484K, E484R, and E484V SARS-CoV-2 circulating mutants. The charged-to-neutral isosteric replacement E484Q has a moderately destabilizing effect (ΔΔG CoV-2 (E484Q) = −2.53 ± 0.16 kcal/mol, Figure 4A , of CIs seen in the wild-type complex, overall resulting in a predicted neutral effect on the related protein/protein interface (ΔΔG CoV-2 (E484D) = −0.61 ± 0.13 kcal/mol, Figure 4A , Table S4 , Figure S1 and Table S5 ).

Q493. According to relevant CAS-based prediction, Q493 also plays a primary stabilizing role at the S-protein/LY-CoV555 mAb interface ( Figure 2B , Tables S1-S2). The analysis of the MD trajectories of all considered mutants (Q493H/K/L/R) reveals that, with respect to the wild-type Q493, all residues except H493 induce a strong destabilizing effect at the interface with the LY-CoV555 mAb ( Figure 5A , Figure S2 , Tables S4 and S6). With R493 as a proofof-principle, Figure 5B shows that this mutant is no longer able to form the three fundamental

HBs across the protein/protein interface with E H 102, and R H 104 on the Ab heavy chain, respectively (see also Table S6 ). Moreover, the spike Y449 no longer engages the side chains of the two LY-CoV555 mAb HC residues T H 28 and S H 31 in polar interactions, leaving the rest of the CI network substantially unchanged (Figures 3B and 5B, Table S6 ). Accordingly, the predicted affinity of this mutant viral protein for the LY-CoV55 mAb is markedly lower than that of the native counterpart (ΔΔG CoV-2 (Q493R) = −4.57 ± 0.11 kcal/mol, Figure 5A , Table S4 ). Analogous effects are predicted for the other two mutants Q493K and Q493L, reflecting in a comparable decrease of protein/protein binding strength (ΔΔG CoV-2 (Q493K) = −4.83 ± 0.12 kcal/mol and ΔΔG CoV-2 (Q493L) = −4.26 ± 0.18 kcal/mol, respectively, Figure   5A , Table S4 , Figure S2 and Table S6 ). These data therefore suggest that the Q493K/L/R mutants could all be LY-CoV555 escaping mutants. At variance with these, mutating Q493

into histidine introduce a somewhat less drastic changes in the topology of the viral proteinantibody interface. In particular, Q493H is still able to preserve one HB with the side chain of the LY-CoV555 R H 104 (3.39 ± 0.15 Å) while the second HB interaction with the same mAb residue is replaced by a p/cation interaction ( Figure S2 , Table S6 ). Notably, the HB between H493 and E H 102 is also missing in the entire MD trajectory of this S-RBD CoV-2 mutant/mAb complex, in addition to the polar CI between Y449 on spike and T H 28 on LY-CoV555 ( Figure   S2 , Table S6 ). In line with this, a moderate variation of the corresponding free energy of binding ( Figure 5A , Table S4 ), that is, ΔΔG CoV-2 (Q493H) = −1.95 ± 0.11 kcal/mol. S494. The third SARS-CoV-2 spike position highlighted by the CAS results as a key residue in binding the LY-CoV555 mAb is S494 ( Figure 2B ). Mutagenesis of this residue into A, P, R, and T reflects into strong interface destabilizing effects, exception made for the S494T substitution for which only a mild effect is observed ( Figure 6A , Table S4 ). In the case of the R494 mutant, the current MD simulations show that both main intermolecular HBs in which the wild-type residue is involved (i.e., S494-E H 102 and S494-R H 104) are longer detected in the trajectory of the correspondent mutant viral protein/mAb complex ( Figure 6B , Table S7 ).

Also, two out of three further stabilizing HBs between the adjacent and important Q493 residue on S-RBD CoV-2 and the side chains of LY-CoV555 E H 102 and R H 104 are no longer formed in the presence of the R494 mutation ( Figures 3B and 6B , Table S7 ). These evidences, along with several missing stabilizing CIs at the protein/protein interface (see Table S7 for details), concur to lower the predicted affinity of the R494 mutant S-RBD CoV-2 for the LY-CoV555 mAb (ΔΔG CoV-2 (S494R) = −5.81 ± 0.17 kcal/mol, Figure 6A , Table S4 ). Accordingly, the three circulating mutants S494A, S494P, and S494R are all predicted to be potential LY-CoV555 escaping variants. (bamlanivimab) mAb as obtained from the relevant equilibrated MD simulation. Images for all other A/P and T mutants are shown in Figure S3 (see also Tables S7 for details) . Colors and other explanations are the same as in Figure 3 .

When S-RBD CoV-2 S494 is mutated into threonine (S494), the MD-predicted interaction network at the corresponding Ab binding interface is only moderately perturbed with respect to that described above for the wild-type complex; in particular, only the HBs between T494

on the SARS-CoV-2 RBD and E H 102 on the HC of LY-CoV555, and between the viral Q493 and the same glutamic acid on the Ab HC are replaced by two polar CIs ( Figure S3 , Table S7 ). In line with this, the related value of ΔΔG CoV-2 (S494T) is slightly unfavorable and equal to -0.70 ± 0.15 kcal/mol ( Figure 6A and Table S4) .

V483, F486, and Y489. The mutagenesis results obtained by mutating these three viral spike amino acids into the reported variants (V483A/F/G/I/L, F486I/L/S, and Y489C/F/H/S, respectively) ultimately confirm the minor role played by these residues at the SARS-CoV-2 RBD/LY-CoV555 mAb binding interface ( Figure 7A -C, Table S4 ). Table S4, Figures S4-S6,   and Tables S8-S10 .

Indeed, the analysis of the respective MD trajectories reveals that each interaction network is practically conserved in all relevant supramolecular assemblies (see Figures S4-S6 and Tables S8-S10 for details). Accordingly, the SARS-CoV-2 spike mutations at residues 483, 486, and 489 reported so far in circulating viral populations are predicted to be tolerated at each respective position. and -albeit to a lower extent -the F490S mutations ( Figure 8A -D, Table S4 , Figures S7-S10 , Tables S11-S14). Figure S8 (see also Tables S12 for details). Colors and other explanations are the same as in Figure 3 .

Together with T470 and F490, the spike residue L452 is a part of a hydrophobic region at the binding interface with LY-CoV555; accordingly, when this amino acid is replaced by the small non-polar methionine or even by the polar glutamine, the corresponding viral/antibody interface remains almost unaffected ( Figures 8B and S8 , Table S12 ). On the contrary, upon mutation of L452 into the positively charged and long-chained asparagine, a substantial modification of the relative binding region is observed in the corresponding MD trajectory, as shown in Figure 8E . Specifically, the structurally-important internal SB between the side chains of LY-CoV555 E H 102 and R H 104 on the Ab HC ( Figure 3B ) is no longer detected, as it is replaced by an analogous yet intermolecular interaction between the former mAb residue and the mutant spike R452 (3.15 ± 0.11 Å). Contextually, however, the formation of this new interface SB is accompanied by the loss of all other crucial intermolecular interactions involving both S-RBD CoV-2 key residues Q493 and S494 ( Figure 8E , Table S12 ). This, in turn, properly reflects in the substantial variation of the corresponding binding free energy value, so that ΔΔG CoV-2 (L452R) = −5.29 ± 0.15 kcal/mol, Figure 8B , Table S4 ), thereby supporting the LY-CoV55 escaping potential of this SARS-CoV-2 spike isoform.

Binding Interface with the LY-CoV016 (Etesevimab) Monoclonal Antibody. Within the same distance and energetic cutoffs adopted for the analysis of the viral S-protein/LY-CoV555 mAb complex (4.0 Å and 0.5 kcal/mol, respectively), the inspection of the equilibrated MD trajectory of the alternative S-RBD CoV-2 /LY-CoV016 mAb assembly reveals that 13 viral protein residues persistent contact 16 residues of the Fab portion of the LY-CoV016 Ab at the 23 relative binding interface. Of the latter, 13 amino acids locate on the mAb HC and 3 belong to the mAb LC, respectively ( Figure 9 , Table S15 ). and all related energy terms, see the text and Tables S16-S17.

According to the CAS results shown in Figure 9B -C (see also Tables S16-S17), and at variance with the binding mode just discussed for the alternative mAb LY-Cov555, the viral RBD/LY-CoV016 binding interface is substantially more diffused and characterized by four distinct regions, the first of which locates in the area centered around the S-RBD CoV-2 residues K417 and N460 ( Figure 10A ). are also indicated using light green/red broken lines and light gray labels (see Table S15 for details and 10A, and Tables S15 and S17). In agreement with this interaction pattern, the K417A mutation in CAS reduces the binding affinity of the corresponding S-RBD CoV-2 for the LY-CoV016 mAb by 6 kcal/mol (ΔΔG CoV-2 (K417A) = −6.01 ± 0.10 kcal/mol, Figure 9B , Table   S16 ). In the same context, the corresponding values of ΔΔG LY-CoV016 (D H 104A) = −2.81 ± 0.15 kcal/mol and ΔΔG LY-CoV016 (Y H 52A) = −1.55 ± 0.11 kcal/mol ( Figure 9C , Table S17) properly rank the relative importance of these LY-Cov016 mAb residues at corresponding viral protein/antibody interface described above.

On the other hand, the S-RBD CoV-2 N460 residue is involved in two permanent HBs with the side chain of S H 56 (3.04 ± 0.09 Å) and with the oxygen atom of the backbone of G H 54 (3.12 ± 0.17 Å), and the relevant value of DDG obtained by CAS for the N460A mutation (ΔΔG CoV-2 (N460A) = −2.75 ± 0.11 kcal/mol, Figure 9B , Table S16 ) confirms the fundamental role of this spike residue at the binding interface. Interestingly, the change in binding free energy predicted by CAS for the S H 56A substitution on the LY-Cov016 mAb (ΔΔG LY-CoV016 (S H 56A) = −3.80 ± 0.16 kcal/mol, Figure 9C , Table S17 ) accounts for the existence of additional stabilizing interactions in this region, characterized by a strong and virtuous network of HBs and CIs. In detail, S H 56 is also involved in two stable HBs with the hydroxyl group of T415 (3.13 ± 0.10 Å, ΔΔG CoV-2 (T415A) = −1.16 ± 0.14 kcal/mol) and the side chain of D420 10A , and Tables S15-S16). Moreover, two additional S-RBD CoV-2 residues concur in determining the stability of the protein/protein interface ( Figure 10A , Table S15 ): Y421

(ΔΔG CoV-2 (Y421A) = −2.47 ± 0.18 kcal/mol) and Q493 (ΔΔG CoV-2 (Q493A) = −1.59 ± 0.14 kcal/mol) ( Figure 9B and Table S15 and S17).

The second important region for the stabilization of the S-RBD CoV-2 /LY-CoV016 complex is mainly composed by the viral residues Y473, N487 and Y489 ( Figure 10B , to binding interface stabilization ( Figure 10B , Table S15, Figure 9C , Table S17 ). Moreover, the S-RBD CoV-2 Y473 (ΔΔG CoV-2 (Y473A) = −2.08 ± 0.12 kcal/mol) is stably engaged in an HB with the side chain of S H 31 (2.83 ± 0.21 Å, ΔΔG LY-CoV016 (S H 31A) = −0.98 ± 0.17 kcal/mol) and in a polar interaction with S H 53 ( Figure 9B-C, Figure10B , Tables S15-S17).

Located in between the two protein/protein interface regions just described, the third binding zone is identified by a network of van der Waals and hydrophobic interactions mainly involving the S-RBD CoV-2 residues L455 (ΔΔG CoV-2 (L455A) = −1.20 ± 0.16 kcal/mol) and F456

(ΔΔG CoV-2 (F456A) = −2.49 ± 0.13 kcal/mol) (see Figures 9B and 10C , Tables S1 and S16).

In particular, this hydrophobic patch at the S-RBD CoV-2 /LY-CoV016 mAb interface sees F456

as the pivot point that coordinates and to appropriately orient the mAb residues Y H 33, S H 53, L H 99, P H 100 and M H 101 for further protein/protein interactions ( Figure 10C , Table S15 ). C and 10D, and Tables S15-S17).

antibody 28 The same data survey reported by Starr and coworkers 57 Table 1 .

K417. Our CAS data highlight the wild-type K417 as a hot-spot residue in the interaction between the S-RBD CoV-2 and the LY-CoV016 mAb ( Figure 9B and 10A, Tables S15-S16).

As such, is not surprising that replacing K417 on the viral protein with each of the alternative circulating mutants (K417E/N/R/T) reflects into a very strong interface disrupting behavior, with the exception of the substitution K417R, for which our in silico mutagenesis data anticipate a neutral effect (Figures 11 and S11 , Tables S18-S19). As seen in Figure 11B and a hydrophobic contact with P H 100 is likewise perturbed when K is replaced by N at the same position ( Figure 11B , Table S19 ). Quite importantly, in the same binding region the presence of N417 affects other protein/protein interactions, including the absence of the three stabilizing HBs between N460 and G H 54, T415 and S H 56, and Y421 and S H 53, respectively ( Figure 11B , Table S19 ). These evidences ultimately translate into a drastically lower affinity of the N417 mutant spike protein for the LY-CoV016 mAb (ΔΔG CoV-2 (K417N) = −7.27 ± 0.07 kcal/mol, Figure 11A and Table S18 ). light yellow, mildly destabilizing mutations; light red, destabilizing mutations; red, highly destabilizing mutations (see Table 1 )

mutant at the interface with the LY-CoV016 (etesevimab) mAb as obtained from the relevant equilibrated MD simulation. Images for the K417E/R/T mutants are shown in Figure S11 (see also Table S19 for details). Colors and other explanations are the same as in Figure 10 .

The effects observed for the E417 and T417 spike mutants are completely similar to those just described for the N417 isoform, although in both these cases the interface HB between the side chains of N460 and G H 54 is again detected yet at the expenses of the analogous interaction between the viral Q493 and the mAb Y H 102, which is missing along the entire MD trajectories of the corresponding supramolecular assemblies. As such, the variation in binding free energy between the wild-type and a mutant spike protein carrying either E or T at position 417 in complex with the LY-CoV016 mAb is predicted to be quite significant (ΔΔG CoV-2 (K417E) = −7.56 ± 0.18 kcal/mol and ΔΔG CoV-2 (K417T) = −7.14 ± 0.09 kcal/mol, Figure 11A , Table   S18 ). On the other hand, only minor interface perturbations are observed in the presence of the R417 mutation ( Figure S11 , Table S19 ), in line with the predicted small change in protein/protein affinity (ΔΔG CoV-2 (K417R) = −0.99 ± 0.15 kcal/mol, Figure 11A , Table S18 ).

D420 and N460. Converting the SARS-CoV-2 spike residues D420 and N460 in alanine via CAS analysis suggests that these two mutant isoforms induce only limited perturbing effects at the relative S-RBD CoV-2 /LY-CoV016 mAb binding interface ( Figures 9B and 10A , and Table S16) . Surprisingly, however, the computational mutagenesis data for all circulating viral mutations at these two spike positions (D420A/G/N and N460I/K/S/T) reveal strong interfacedestabilizing effects in all cases, with difference in free energy of binding with respect to the wild-type protein ranging from ~ -5 to ~ -3 kcal/mol (i.e., ΔΔG CoV-2 (D420A) = −4.36 ± 0.17 kcal/mol, ΔΔG CoV-2 (D420G) = −4.39 ± 0.10 kcal/mol, ΔΔG CoV-2 (D420N) = −4.23 ± 0.10 kcal/mol, ΔΔG CoV-2 (N460I) = −5.01 ± 0.14 kcal/mol, ΔΔG CoV-2 (N460K) = −3.28 ± 0.18 kcal/mol, ΔΔG CoV-2 (N460S) = −4.06 ± 0.09 kcal/mol, ΔΔG CoV-2 (N460T) = −4.12 ± 0.14 kcal/mol) (see also Table S18 ). also Tables S20-S21 for   details) . Colors and other explanations are the same as in Figure 10 .

The molecular rationale for these results relies not only on the fact all D420 and N460 S-RBD CoV-2 variants remove all direct interactions provided by aspartic acid (420) or glutamine (460) but also exert a domino effect on the nearby spike residues populating the same binding region, including T415 and, above all, the hot spot K417. Considering A420 as an exemplar of all D420 mutant behavior, from Figure 12B it is quickly seen that the wild-type HB with the side chain of S H 56 is evidently missing, as are the three topical HBs between T415 and S H 56, between K417 and Y H 52, and between N460 and G H 54, respectively (see also Figure S12 and and S H 53 across the respective protein/protein interface ( Figures 12D and S13 , Table S21 ). (Figures 13A-B and S14-S15, Tables S18 and S22-23). Table S22 ), ultimately resulting in a limited decrement of the corresponding free energy variations ( Figure 13A , Table S18 ). In the case of the T415P variant, the remarkably negative effect on spike/mAb affinity predicted by our in silico mutagenesis is sensibly linked -aside for the same perturbating effects just discussed for the other mutations at the same viral protein location -to the absence of the additional interface HB and CIs between the side chains of Q493 on the spike and of Y H 102 on the mAb HC ( Figure 13C , Table   S22 ). Accordingly, the S-RBD CoV-2 T415P mutation reported so far in circulating viral populations is predicted to be potentially destabilizing for the S-RBD CoV-2 /LY-CoV016 interface (ΔΔG CoV-2 (T415P) = −2.83 ± 0.07 kcal/mol, Figure 13A and Table S18 ).

Y473, N487 and Y489. These viral residues belong to the spike/LY-Cov016 binding region that, according to the relevant MD trajectories, is characterized by an important network of stabilizing hydrogen bonds. Nevertheless, the present computational mutagenesis data report only neutral-to-mild interface destabilizing effects for the circulating SARS-CoV-2 RBD variants of Y473 (Y473F/H) and N487 (N487D) (see Table S18 , Figures S16-S17, and Tables   S24-S25 for Table S18 , Figure S16 , Table S24 ).

The predicted minor loss in binding affinity of the D487 spike variant for the LY-CoV016 mAb (ΔΔG CoV-2 (N487D) = −0.70 ± 0.09 kcal/mol, Table S18 ), on the other hand, is the result of a compensatory effect as the mutant aspartic acid provides a permanent intermolecular SB with the guanidine group of the Ab R H 97 that makes up for the loss of the two HBs between Y473

and S H 31 and Y489 and R H 97, respectively (Figures 10B and S17 , Table S25 ).

Finally, according to our MD analysis the circulating Y489 S-RBD CoV-2 variants induce a moderate decrease in affinity of the viral spike protein for the LY-CoV016 mAb ( Figure 14A , Table S18 ). In particular, the conversion of tyrosine 489 into cysteine or serine results in the abrogation of the direct HB with R H 97 as well as the hydrophobic contact with L H 99.

Moreover, the HB involving Y473 and S H 31 is also missing along the entire MD trajectories of the Y489C and Y489S S-RBD CoV-2 mutant proteins, as shown in Figure 14B for the S489 isoform (see also Figure S18 and Table S26 ). Table S18 , Figure S18 and Table S26 Figure S18 (see also Table S26 for details). Colors and other explanations are the same as in Figure 10 .

In line with this, the calculated DDG values numerically support moderate interface destabilizing effects upon substitution of the wild-type tyrosine with these two residues (ΔΔG CoV-2 (Y489C) = −2.15 ± 0.10 kcal/mol, and ΔΔG CoV-2 (Y489S) = −2.41 ± 0.07 kcal/mol, respectively, Figure 14A and Table S18) . Table   S18 , Figures S19-S22 and Tables S27-S30). Table S18, Figures   S19-S22 and Tables S27-S30 .

Therefore, all these SARS-CoV-2 spike position variants do not appear to have a significant role in escaping the LY-CoV016 antibody. The purpose of this work was to provide an in silico molecular rationale of the role eventually played by currently circulating S-RBD CoV-2 mutations in evading the immune surveillance effects elicited by the two Eli Lilly LY-CoV555/bamlanivimab and LY-CoV016/etesevimab monoclonal antibodies. Table 2 summarizes the main findings from this study and shows that, compared to the wild-type SARS-CoV-2 spike protein, all mutants highlighted in light or dark red are predicted to be markedly more resistant to neutralization by both these mAbs, those shown in yellow might exert only mildly perturbing protein/protein binding, while those listed in gray are not likely to confer any mAb escaping advantage to the viral protein. Table 2 . Color-code ranking of circulating SARS-CoV-2 spike protein mutants with respect to their predicted resistance to neutralization by LY-CoV-555 (bamlanivimab) and LY-CoV016

(etesevimab) monoclonal antibodies. Colors as in Table 1 . Mutating the wild-type spike F490 into alanine also flagged this position as a residue affording an important contribution to the protein/protein interface ( Figure 2A , Table S2 ).

Interestingly, the corresponding mutagenesis into all reported variants (F490L/S/V/Y) revealed that only the F490S spike mutant is a potential escapee for LY-CoV555 (Figures 8, (Figures 2A and 3B , Table S2 ).

In silico mutagenesis of Q493 and S494 into the circulating variants (Q493H/K/L/R, and S494A/P/R/T) not only confirms Lilly's data about Q493R and S494P as resistant mutations for LY-CoV555 59 but also predicts a potential role of other substitutions at these two S-protein positions (i.e., Q493K/L and S494A/P/R) in mediating evasion to this mAb ( Figures 5-6 , Table   2 ). In line with these predictions, three new studies highlighted all these mutants as vir al proteins that may hinder the efficiency of existing vaccines and expand in response to the increasing after-infection or vaccine-induced seroprevalence. 66 Table 2 ), while we did not detect any effect in terms of changed affinity of this mutant protein toward etesevimab. Moreover, our data also suggest that the co-presence of the E484Q ( Figure 5 , Table 2 Concerning the alternative LY-CoV016 mAb, the official Lilly's fact sheet 59 reports that SARS-CoV-2 spike mutants showing reduced susceptibility to etesevimab include substitutions K417N, D420N, and N460K/S/T. In agreement with this and other evidences, 72, 79 our current computational alanine/mutagenesis study marks K417 and all its reported variants (K417E/N/R/T) as the strongest hot spots in eliciting potential escape to the LY-CoV016 mAb ( Figure 11A , Table 2 ). Of note, the K417N and K417T in particular are spike MOIs in the SARS-CoV2 VOC lineages B.1.351 and P.1, respectively. Similarly, not only the D420N but all reported circulating spike mutations at positions 420 are predicted by our study to be endowed with high LY-CoV016 escaping potential ( Figure 12A , Table 2 ), in line with recent findings. 79 Finally, and in full agreement with Lilly's data, 59 LY-CoV016 is also found to be escaped by all spike N460 variations (N460I/K/S/T) ( Figure 12C , Table 2 ).

In addition, in the current study we identify three further single amino acid changes along the primary sequence of SARS-CoV-2 spike protein that -although not reported as current VOC/VOI/VUM -could escape the action of LY-CoV016, that is the T415P and the Y489C/S mutations ( Figures 13A and 14A, Table2 ). Since these spike mutants are present in circulating viral variants, in our opinion they should be taken into consideration as they might limit the therapeutic usefulness of this mAb, both per se and in its cocktail combination with LY-CoV555.

As a conclusive remark concerning available anti-SARS-CoV-2 vaccines, according to the report by Andreano 87 In all these cases, the spike E484K mutation appears to be the real key player in reducing neutralization by antibodies induced by the vaccines. And this, in turn, support the view that vaccination elicits a natural infection-like antibody response, and that spike variants like E484K may spread as antigenic evolutions of SARS-CoV-2 to efficiently evade this response. On the bright side, all vaccines currently approved appear at least to protect from the severe forms of infection, 88, 89 and second-generation vaccines and mAbs aiming at containing VOC spreading are under investigation. 90 In concluding this work, we report that a challenge of our global in silico results against the relevant experimental data just published by the Starr group 57 resulted in an overall 90% agreement. This achievement not only constitutes a further, robust validation of our computerbased approach but also yields a molecular-based rationale for all relative experimental findings, and leads us to conclude that the current circulating SARS-CoV-2 and all possible emergent variants carrying these mutations in the spike protein can present new challenges for mAb-based therapies and ultimately threaten the fully-protective efficacy of currently available vaccines.

Characteristics of SARS-CoV-2 and COVID-19

Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review

China Novel Coronavirus Investigating Research Team, A Novel Coronavirus from Patients with Pneumonia in China

Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review

Cytokine Storm in COVID-19: The Current Evidence and Treatment Strategies

Is a "Cytokine Storm" Relevant to COVID-19?

COVID-19 Vaccines: Where We Stand and Challenges Ahead

A Comprehensive Review of the Global Efforts on COVID-19 Vaccine Development

A Systematic Review of Antibody Mediated Immunity to Coronaviruses: Kinetics, Correlates of Protection, and Association with Severity

Neutralizing Antibodies Against SARS-CoV-2 and Other Human Coronaviruses

Neutralizing Antibodies Against SARS-CoV-2-Important Questions, Unclear Answers

COVID-19 Antibodies on Trial

Development and Application of

Therapeutic Antibodies Against COVID-19

Covid-19: RECOVERY Trial Will Evaluate

Neutralizing Monoclonal Antibodies for Treatment of COVID-19

Developments and Challenges for mAb-Based Therapeutics

Development of Therapeutic Antibodies for the Treatment of Diseases

Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein

Structural Analysis of Full-Length SARS-CoV-2 Spike Protein from an Advanced Vaccine Candidate

Cryo-EM Structure of the 2019-nCoV Spike in the Prefusion Conformation

Structure of the SARS-CoV-2 Spike Receptor-Binding Domain Bound to the ACE2 Receptor

Structural Basis for the Recognition of SARS-CoV-2 by Full-Length Human ACE2

Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2

Receptor Binding and Priming of the Spike Protein of SARS-CoV-2 for Membrane Fusion

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Priming of SARS-CoV-2 S Protein by Several Membrane-Bound SerineProteinases Could Explain Enhanced Viral Infectivity and Systemic

Neutralizing Antibodies Targeting SARS-CoV-2 Spike Pprotein

Antibodies and Vaccines Target RBD of SARS-CoV-2. Front. Mol

SARS-CoV-2 Neutralizing Human Recombinant Antibodies Selected from Pre-Pandemic Healthy Donors Binding at RBD-ACE2 Interface

Receptor-Binding Domain-Specific Human Neutralizing Monoclonal Antibodies Against SARS-CoV and SARS-CoV-2

Cross-Neutralization of SARS-CoV-2 by a Human Monoclonal SARS-CoV Antibody

Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology

Persistence and Decay of Human Antibody Responses to the Receptor Binding Domain of SARS-CoV-2 Spike Protein in COVID-19

Key Residues of the Receptor Binding Motif in the Spike Protein of SARS-CoV-2 that Interact with ACE2 and Neutralizing Antibodies

LY-CoV555, a Rapidly Isolated Potent Neutralizing Antibody, Provides Protection in a Non-Human PrimateModel of SARS-CoV-2 Infection

NCT04411628: A Study of LY3819253 (LY-CoV555) in Participants Hospitalized for COVID-19. Official title: A Randomized, Placebo-Controlled, Double-Blind

Official title: A Randomized, Double-blind, Placebo-Controlled, Phase 2/3 Study to Evaluate the Efficacy and Safety of LY3819253 and LY3832479 in Participants with Mild to Moderate

NCT04497987: A Study of LY3819253 (LY-CoV555) and LY3832479

Official Title: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of LY3819253 Alone and in Combination with LY3832479 in Preventing SARS-CoV-2 Infection and COVID-19 in Skilled Nursing and Assisted Living Facility Residents and Staff; a NIAID and Lilly Collaborative Study

Viral and host heterogeneity and their effects on the viral life cycle

Coronavirus RNA Proofreading: Molecular Basis and Therapeutic Targeting

Coronavirus Biology and Replication: Implications for SARS-CoV-2

Complexities of Viral Mutation Rates

Evidence for Host-Dependent RNA Editing in the Transcriptome of SARS-CoV-2

We Shouldn't Worry When a Virus Mutates During Disease Outbreaks

Alarming COVID Variants Show Vital Role of Genomic Surveillance

Prospects for Durable Immune Control of SARS-CoV-2 and Prevention of Reinfection

Neutralizing Antibodies Against SARS-CoV-2: Current Understanding, Challenge and Perspective

Neutralizing Monoclonal Antibodies for Treatment of COVID-19

Computational Alanine Scanning and Structural Analysis of the SARS-CoV-2 Spike Protein/Angiotensin-Converting Enzyme 2 Complex

Complete Map of SARS

CoV-2 RBD Mutations that Escape the Monoclonal Antibody LY-CoV555 and Its Cocktail with LY-CoV016. Cell Rep

Computational Mutagenesis at the SARS-CoV-2 Spike Protein/Angiotensin-Converting Enzyme 2 Binding Interface: Comparison with Experimental Evidence

Escape from Neutralizing Antibodies by SARS-CoV-2 Spike Protein Variants. Elife 2020

Infection Is Largely Shaped by a Single Class of Antibodies

The Great Escape? SARS-CoV-2 Variants Evading Neutralizing Responses

Resistance of SARS-CoV-2 Variants to Neutralization by Monoclonal and Serum-Derived Polyclonal Antibodies

SARS-CoV-2 Spike E484K Mutation Reduces Antibody Nneutralisation

SARS-CoV-2 Variant of Concern 202012/01 Has about Twofold Replicative Advantage and Acquires Concerning Mutations

Multiple SARS-CoV-2 Variants Escape Neutralization by Vaccine-Induced Humoral Immunity

Comprehensive Mapping of Mutations in the SARS-CoV-2 Receptor-Binding Domain that Affect Recognition by Polyclonal Human Plasma Antibodies

A Novel SARS-CoV-2 Variant of Concern, B.1.526, Identified in New York

SARS-CoV-2 501Y.V2 Variants Lack Higher Infectivity but Do Have Immune Escape

Escape of SARS-CoV-2 501Y.V2 from Neutralization by Convalescent Plasma

Neutralising Antibody Escape of SARS-CoV-2 Spike Protein: Risk Assessment for Antibody-Based Covid-19 Therapeutics and Vaccines

501Y.V2 and 501Y.V3 Variants of SARS-CoV-2 Lose Binding to Bamlanivimab in Vitro

Identification of SARS-CoV-2 Spike Mutations that Attenuate Monoclonal and Serum AntibodyNeutralization

Antibody Evasion by the P.1 Strain of SARS-CoV-2

Comparative Analysis of Emerging B.1.1.7+E484K SARS-CoV-2 Isolates from Pennsylvania

Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA Vaccine-Elicited Antibodies

Revealing the Threat of Emerging SARS

CoV-2 Mutations to Antibody Therapies. bioRxiv 2021

One-Shot Identification of SARS-CoV-2 S RBD Escape Mmutants Using Yeast Screening

Transmission, Infectivity, and Antibody Neutralization of an Emerging SARS-CoV-2 Variant in California Carrying a L452R Spike Protein Mutation

An Emerging SARS-CoV-2 Mutant Evading Cellular Immunity and Increasing Viral Infectivity. bioRxiv 2021

SARS-CoV-2 Immune Evasion by Variant B.1.427/B.1.429. bioRxiv 2021

The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and Antigenicity

SARS-CoV-2 Variant B.1.617 Is resistant to Bamlanivimab and Evades Antibodies Induced by Infection and Vaccination

SARS-CoV-2 escaped natural immunity, raising questions about vaccines and therapies

Sensitivity of Infectious SARS-CoV-2 B.1.1.7 and B.1.351 Variants to Neutralizing Antibodies

How to Redesign COVID Vaccines so They Protect Against Variants